386 related articles for article (PubMed ID: 33094669)
1. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.
Zhou Z; Price CC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1407-1412. PubMed ID: 33094669
[TBL] [Abstract][Full Text] [Related]
2. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
Du P; Geng J; Wang F; Chen X; Huang Z; Wang Y
Int J Med Sci; 2021; 18(6):1356-1362. PubMed ID: 33628091
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
4. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
5. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
Atal S; Fatima Z
Pharmaceut Med; 2020 Aug; 34(4):223-231. PubMed ID: 32535732
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
[TBL] [Abstract][Full Text] [Related]
8. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
Cure E; Kucuk A; Cure MC
Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
10. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
[TBL] [Abstract][Full Text] [Related]
11. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
León López R; Fernández SC; Limia Pérez L; Romero Palacios A; Fernández-Roldán MC; Aguilar Alonso E; Pérez Camacho I; Rodriguez-Baño J; Merchante N; Olalla J; Esteban-Moreno MÁ; Santos M; Luque-Pineda A; Torre-Cisneros J
BMJ Open; 2020 Nov; 10(11):e039951. PubMed ID: 33191263
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
Khiali S; Khani E; Entezari-Maleki T
J Clin Pharmacol; 2020 Sep; 60(9):1131-1146. PubMed ID: 32557541
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review on sarilumab in COVID-19.
Khiali S; Rezagholizadeh A; Entezari-Maleki T
Expert Opin Biol Ther; 2021 May; 21(5):615-626. PubMed ID: 33161757
[No Abstract] [Full Text] [Related]
15. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
16. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
Ali A; Kamjani MH; Kesselman MM
Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
[TBL] [Abstract][Full Text] [Related]
17. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
[TBL] [Abstract][Full Text] [Related]
18. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.
Oliynyk O; Barg W; Slifirczyk A; Oliynyk Y; Gurianov V; Rorat M
Viruses; 2021 Jun; 13(6):. PubMed ID: 34205217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
